Rein Therapeutics (RNTX) Accumulated Depreciation & Amortization (2016 - 2023)
Rein Therapeutics (RNTX) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $358000.0 as the latest value for Q4 2023.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 32.59% to $358000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $358000.0, a 32.59% increase, with the full-year FY2023 number at $358000.0, up 32.59% from a year prior.
- Accumulated Depreciation & Amortization was $358000.0 for Q4 2023 at Rein Therapeutics, up from $272000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $522000.0 in Q4 2019 to a low of $166000.0 in Q4 2020.
- A 5-year average of $279500.0 and a median of $255000.0 in 2022 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: tumbled 68.2% in 2020, then soared 32.59% in 2023.
- Rein Therapeutics' Accumulated Depreciation & Amortization stood at $522000.0 in 2019, then crashed by 68.2% to $166000.0 in 2020, then grew by 27.71% to $212000.0 in 2021, then grew by 27.36% to $270000.0 in 2022, then skyrocketed by 32.59% to $358000.0 in 2023.
- Per Business Quant, the three most recent readings for RNTX's Accumulated Depreciation & Amortization are $358000.0 (Q4 2023), $272000.0 (Q1 2023), and $270000.0 (Q4 2022).